Teva Pharmaceutical Industries Ltd (TEVJF) FCF Margin (2009 - 2026)
Teva Pharmaceutical Industries' (TEVJF) quarterly FCF Margin came in at 7.41% in Q2 2026, up 427.0% YoY from 1.41% in Q2 2025, and up 241.89% on a QoQ basis from 5.22% in Q1 2026.
Teva Pharmaceutical Industries Ltd (TEVJF) FCF Margin (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVJF) has 18 years of FCF Margin data on file, last reported at 7.41% in Q2 2026.
- Quarterly FCF Margin rose 427.0% year-over-year to 7.41% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 7.79% (up 197.0% YoY) and the FY2025 annual result came in at 6.65%, up 212.0% from the prior year.
- FCF Margin grew to 7.41% in Q2 2026, from 5.22% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 23.89% in Q4 2023 to a low of 7.76% in Q1 2023.
- A 5-year average of 5.16% and a median of 4.17% in 2025 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2023 — FCF Margin slumped 1545 bps — and 2024, when it jumped 1632 bps.
- Tracing TEVJF's FCF Margin over 5 years: stood at 21.4% in 2022, then climbed by 12 bps to 23.89% in 2023, then tumbled by 36 bps to 15.38% in 2024, then soared by 40 bps to 21.57% in 2025, then tumbled by 66 bps to 7.41% in 2026.
- The last three FCF Margin figures came in at 7.41% (Q2 2026), 5.22% (Q1 2026), and 21.57% (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.41% |
| Mar 31, 2026 | -5.22% |
| Dec 31, 2025 | 21.57% |
| Sep 30, 2025 | 5.20% |
| Jun 30, 2025 | 3.14% |
| Mar 31, 2025 | -5.96% |
| Dec 31, 2024 | 15.38% |
| Sep 30, 2024 | 12.58% |
| Jun 30, 2024 | 0.14% |
| Mar 31, 2024 | -6.49% |
| Dec 31, 2023 | 23.89% |
| Sep 30, 2023 | -3.74% |
| Jun 30, 2023 | 5.29% |
| Mar 31, 2023 | -7.76% |
| Dec 31, 2022 | 21.40% |
| Sep 30, 2022 | 11.71% |
| Jun 30, 2022 | -0.11% |
| Mar 31, 2022 | -5.63% |
| Dec 31, 2021 | 7.39% |
| Sep 30, 2021 | 9.85% |